Model for End-stage Liver Disease

Ashwani K. Singal, Patrick S. Kamath

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations

Abstract

Model for end-stage liver disease (MELD) score, initially developed to predict survival following transjugular intrahepatic portosystemic shunt was subsequently found to be accurate predictor of mortality amongst patents with end-stage liver disease. Since 2002, MELD score using 3 objective variables (serum bilirubin, serum creatinine, and institutional normalized ratio) has been used worldwide for listing and transplanting patients with end-stage liver disease allowing transplanting sicker patients first irrespective of the wait time on the list. MELD score has also been shown to be accurate predictor of survival amongst patients with alcoholic hepatitis, following variceal hemorrhage, infections in cirrhosis, after surgery in patients with cirrhosis including liver resection, trauma, and hepatorenal syndrome (HRS). Although, MELD score is closest to the ideal score, there are some limitations including its inaccuracy in predicting survival in 15-20% cases. Over the last decade, many efforts have been made to further improve and refine MELD score. Until, a better score is developed, liver allocation would continue based on the currently used MELD score.

Original languageEnglish (US)
Pages (from-to)50-60
Number of pages11
JournalJournal of Clinical and Experimental Hepatology
Volume3
Issue number1
DOIs
StatePublished - Mar 2013

Keywords

  • Cirrhosis
  • Liver transplantation
  • MELD

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Model for End-stage Liver Disease'. Together they form a unique fingerprint.

Cite this